Idioma:

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

MAGNE TVEIT, Kjell ; GUREN, Tormod ; FOKSTUEN, Tone ; HANSEN, Flemming ; HOFSLI, Eva ; BIRKEMEYER, Elke ; JOHNSSON, Anders ; STARKHAMMAR, Hans ; YILMAZ, Mette Karen ; KELDSEN, Nina ; BERIT ERDAL, Anne ; DAJANI, Olav ; GLIMELIUS, Bengt ; DAHL, Olav ; CHRISTOFFERSEN, Thoralf ; PFEIFFER, Per ; SORBYE, Halfdan ; PYRHONEN, Seppo ; SIGURDSSON, Fridbjorn ; KURE, Elin ; IKDAHL, Tone ; SKOVLUND, Eva

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1755-1762 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por

Enviar para

Título:
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
Autor: MAGNE TVEIT, Kjell ; GUREN, Tormod ; FOKSTUEN, Tone ; HANSEN, Flemming ; HOFSLI, Eva ; BIRKEMEYER, Elke ; JOHNSSON, Anders ; STARKHAMMAR, Hans ; YILMAZ, Mette Karen ; KELDSEN, Nina ; BERIT ERDAL, Anne ; DAJANI, Olav ; GLIMELIUS, Bengt ; DAHL, Olav ; CHRISTOFFERSEN, Thoralf ; PFEIFFER, Per ; SORBYE, Halfdan ; PYRHONEN, Seppo ; SIGURDSSON, Fridbjorn ; KURE, Elin ; IKDAHL, Tone ; SKOVLUND, Eva
Assuntos: Adult ; Aged ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cancer and Oncology ; Cancer och onkologi ; Cetuximab ; Clinical Medicine ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - secondary ; Disease-Free Survival ; DNA Mutational Analysis ; Drug Administration Schedule ; Europe ; Female ; Fluorouracil - administration & dosage ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Kaplan-Meier Estimate ; Klinisk medicin ; Leucovorin - administration & dosage ; Male ; Medical and Health Sciences ; Medical sciences ; MEDICIN ; Medicin och hälsovetenskap ; MEDICINE ; Middle Aged ; Mutation ; Organoplatinum Compounds - administration & dosage ; Proportional Hazards Models ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins B-raf - genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins - genetics ; Risk Assessment ; Risk Factors ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Time Factors ; Treatment Outcome ; Tumors
É parte de: Journal of clinical oncology, 2012-05, Vol.30 (15), p.1755-1762
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Undefined-2
ObjectType-News-4
Descrição: The NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic colorectal cancer (mCRC). The influence of KRAS mutation status on treatment outcome was also investigated. Patients were randomly assigned to receive either standard Nordic FLOX (arm A), cetuximab and FLOX (arm B), or cetuximab combined with intermittent FLOX (arm C). Primary end point was progression-free survival (PFS). Overall survival (OS), response rate, R0 resection rate, and safety were secondary end points. Of the 571 patients randomly assigned, 566 were evaluable in intention-to-treat (ITT) analyses. KRAS and BRAF mutation analyses were obtained in 498 (88%) and 457 patients (81%), respectively. KRAS mutations were present in 39% of the tumors; 12% of tumors had BRAF mutations. The presence of BRAF mutations was a strong negative prognostic factor. In the ITT population, median PFS was 7.9, 8.3, and 7.3 months for the three arms, respectively (not significantly different). OS was almost identical for the three groups (20.4, 19.7, 20.3 months, respectively), and confirmed response rates were 41%, 49%, and 47%, respectively. In patients with KRAS wild-type tumors, cetuximab did not provide any additional benefit compared with FLOX alone. In patients with KRAS mutations, no significant difference was detected, although a trend toward improved PFS was observed in arm B. The regimens were well tolerated. Cetuximab did not add significant benefit to the Nordic FLOX regimen in first-line treatment of mCRC.
Editor: Alexandria, VA: American Society of Clinical Oncology
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

Alexandria, VA: American Society of Clinical Oncology

Buscando em bases de dados remotas. Favor aguardar.